Shots:

• Polpharma Biologics has reported that its JV company- Bioeq collaborates with Teva to commercialize Bioeq’s FYB201 (biosimilar referencing Lucentis) in the EU- Canada- Israel & New Zealand
• The launch of biosimilar ranibizumab may increase market competition- reduce cost and expand patient access with proven analytical & clinical similarity to Lucentis while FYB201 was originally licensed from Formycon AG
• The recent agreement with Teva complements a previous agreement with Coherus BioScience for commercialization in the US. Lucentis is a mAb fragment that has been approved to treat wet AMD

  Ref: Businesswire | Image: Bioeq